Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» FHD-286
FHD-286
Foghorn Therapeutics doses first patient in AML therapy trial
Clinical Trials Arena
Fri, 09/1/23 - 11:57 am
Foghorn Therapeutics
FHD-286
AML
Foghorn Abandons Uveal Melanoma Program after Subpar Phase I Results
BioSpace
Thu, 06/29/23 - 11:48 am
Foghorn Therapeutics
uveal melanoma
AML
FHD-286
Foghorn sinks plans for eye tumor drug after glimpsing phase 1 data
Fierce Biotech
Wed, 06/28/23 - 10:30 am
Foghorn Therapeutics
FHD-286
eye cancer
clinical trials
Foghorn finally has clear route back to clinic after FDA lifts yearlong hold on blood cancer drug
Fierce Biotech
Tue, 06/6/23 - 10:01 am
Foghorn Therapeutics
FHD-286
FDA
blood cancer
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
BioSpace
Tue, 08/23/22 - 10:35 am
Foghorn Therapeutics
FHD-286
AML
MDS
FDA
clinical trials
FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial
Benzinga
Fri, 05/20/22 - 10:28 am
Foghorn Therapeutics
clinical trials
FDA
FHD-286
acute myelogenous leukemia
AML
patient death